50 - “Integrating In Silico and In Vivo Data to Optimize Plerixafor Treatment for ARDS”
Abstract
ARDS is a life-threatening condition with limited treatment options. Leveraging in silico simulations and in vivo preclinical data, this study identifies optimal patient responders. Plerixafor shows promise in reducing NETosis, particularly in intubated patients and across ARDS etiologies. Targeting a specific subpopulation based on severity, not etiology, is crucial. Plerixafor's efficacy underscores the importance of integrating in silico and in vivo data for personalized ARDS treatment.
Bios
Amichai Perlman PharmD PhD, clinical data scientist at QuantHealth and senior lecturer at the Hebrew University of Jerusalem.
Dr. Amichai Perlman is a dynamic clinical pharmacologist and pharmacoepidemiologist blending clinical expertise with cutting-edge research. Currently, he's a Clinical Data Scientist at QuantHealth, where he engages in developing novel approaches to inform clinical trial design and clinical trial simulation. Dr. Perlman holds a PhD and PharmD from the Hebrew University of Jerusalem, where he also serves as a member of the academic faculty. As a Senior Lecturer, he brings clinical data science to life for students, guiding them through projects evaluating medication efficacy and safety using real world data. Dr. Perlman’s journey includes R&D experience at K-Health, leading innovative research on healthcare records and digital health products, as well as deep clinical experience, having served as a Clinical Pharmacist Consultant at Hadassah University Medical Center. Dr. Perlman has a prolific publication record, with significant contributions to journals such as CNS Drugs, Drug Safety, Chest, Journal of the American Medical Directors Association, Annals of Pharmacotherapy, and Nutrition, Metabolism and Cardiovascular Diseases. His academic achievements are complemented by numerous awards, including the Yael Nusbaum-Lev Award for Excellence in PhD Research and prizes from the Pharmaceutical Society of Israel and Merck innovation hackathon.
Revital Rattenbach, MBA-PhD, Founder and CEO 4P-Pharma
Revital Rattenbach has a Ph.D. in Biology from the University René Descartes and an MBA from Sorbonne University. With over 15 years of experience in the creation, financing, and strategy of biotechnology start-ups, she founded 4P-Pharma.
At 4P-Pharma, Revital established the company’s drug regeneration business model. The model is built around a platform for the internal evaluation of academic innovations, which are then valorized through asset-centric subsidiaries.
Revital also co-founded and managed Adstem, a spin-off from the University Paris VI, which developed adult stem cell activation therapies. She also co-founded Pharmaseed Europe, specializing in early-stage pharmaceutical development.
Additionally, she is an independent board member of Biosenic, a Belgian-listed company.
